Our view
Over the last few years, FDA has increased inspections of foreign facilities in order to address
concerns related to the quality of APIs and formulated drugs manufactured overseas. This is
reflected in the dramatic increase in warning letters issued to manufacturers in countries like India
and China.
However, refusing an FDA inspection is a new trend. Companies often refuse an inspection if they
arent prepared for one, or if they find it unreasonable on part of the FDA to inspect a particular
office or facility.
For instance, a facility many not even be exporting drugs to the US. Or in the case of Divis, the
executives may have found it unwarranted to inspect their corporate office.
While manufacturers in India and China need to prepare themselves for more of such surprise
inspections, the FDA on its part needs to ensure that the inspection is indeed warranted.
Errata: This is an updated version of the story. This website inaccurately mentioned Divis
Laboratories in its headline in the version posted on Aug 31, 2016. The error is regretted.